文献速递神经核医学骨显像与常规 SPECT

前驱期与临床期帕金森病的颅骨葡萄糖代谢模式:18F-FDG PET 揭示

Cranial glucose metabolic patterns across prodromal and clinical parkinson's disease revealed by 18F-FDG PET.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-03

这项前瞻性横断面研究纳入190名参与者(34名对照、32名前驱期帕金森病、50名新发帕金森病、74名药物治疗帕金森病),用脑18F-FDG PET评估颅骨葡萄糖摄取。临床确诊的帕金森病患者在颅骨、额骨、蝶骨和顶骨呈现高代谢,而前驱期个体未见此模式;空腹血糖为正性调节因素,多巴胺能药物为负性调节因素。

要点

  • 临床确诊帕金森病(新发和药物治疗)较健康对照在颅骨、额骨、蝶骨和顶骨显示高代谢(p < 0.05)。
  • 药物治疗帕金森病较健康对照在颞骨和枕骨也显示高代谢(p < 0.05),前驱期个体未见此代谢模式。
  • 空腹血糖为正性调节因素(β = 0.020 ~ 0.043,p < 0.05),多巴胺能药物为负性调节因素(β = -1.207 × 10-4 ~ -9.482 × 10-5,p < 0.005)。

核心结论

  • 本研究揭示了帕金森病患者的颅骨代谢异常,为帕金森病相关骨共病的病理生理机制提供了新视角。

研究设计与样本

  • 前瞻性横断面研究,纳入190名参与者,包括34名对照、32名前驱期帕金森病、50名新发帕金森病和74名药物治疗帕金森病患者。
  • 药物治疗帕金森病患者进一步分为早期、中期和晚期3个阶段。
  • 采用一般线性模型比较对照组、前驱期帕金森病、新发帕金森病和药物治疗帕金森病患者的颅骨葡萄糖摄取,以及不同阶段药物治疗帕金森病患者间的差异。
  • 采用多元线性回归评估运动功能、疾病病程和多巴胺能药物对颅骨葡萄糖摄取的影响。

主要发现

  • 临床确诊的帕金森病患者(新发和药物治疗)较健康对照在颅骨、额骨、蝶骨和顶骨显示高代谢(p < 0.05)。
  • 药物治疗帕金森病患者较健康对照在颞骨和枕骨也显示高代谢(p < 0.05)。
  • 前驱期个体未观察到上述代谢模式。
  • 多元线性回归识别空腹血糖为正性调节因素(β = 0.020 ~ 0.043,p < 0.05),多巴胺能药物为负性调节因素(β = -1.207 × 10-4 ~ -9.482 × 10-5,p < 0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bone plays pivotal roles in glucose homeostasis of the human body. Parkinson's disease (PD) is accompanied by metabolic dysfunction and increased risks of bone diseases. Nevertheless, whether PD affects bone glucose metabolism remains unknown. This study aimed to assess cranial glucose metabolism in different stages of PD using brain 18F-fludeoxyglucose positron emission tomography (18F-FDG PET). METHODS: This prospective cross-sectional study included 190 participants, including 34 controls, 32 prodromal PD (pPD), 50 de novo PD (dnPD) and 74 medicated PD (mPD) patients. mPD patients were further separated into 3 stages: early-, middle- and late-stage PD patients. Comparisons of glucose uptake in the cranium was assessed using general linear model among controls, pPD, dnPD and mPD patients, as well as among mPD patients with different stages. Furthermore, effects of motor function, disease duration and dopaminergic medication on cranial glucose uptake were assessed using multiple linear regression. RESULTS: The results demonstrated cranial hypermetabolism in clinically confirmed PD patients (dnPD and mPD patients) compared to HCs in the cranium, frontal, sphenoid and parietal bones (p < 0.05). In addition, mPD patients also demonstrated hypermetabolism in temporal and occipital bones compared to HCs (p < 0.05). However, this metabolic pattern was not observed in the prodromal individuals. Moreover, multiple linear regression identified fasting blood glucose as a positive modulator (β = 0.020 ~ 0.043, p < 0.05) and dopaminergic medication as a negative regulator (β=-1.207 × 10-4~-9.482 × 10-5, p < 0.005) of cranial glucose metabolic activity. CONCLUSION: The current study uncovered cranial metabolic abnormalities in PD, offering new perspectives and pathophysiological insights underlying bone-related comorbidities in PD.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lu W, Song T, Zhou Y, et al. Cranial glucose metabolic patterns across prodromal and clinical parkinson's disease revealed by 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2025. PMID: 40900316. doi:10.1007/s00259-025-07533-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。